Financings in Brief: Matritech
This article was originally published in The Gray Sheet
Executive Summary
Matritech: Developer of the NMP (nuclear matrix protein) technology for cancer detection files registration statement for the sale of 2 mil. shares, including 1.8 mil. to be sold by the company and 200,000 by shareholders. Matritech will have about 17.8 mil. outstanding shares after the offering. Montgomery Securities and Genesis Merchant Group Securities are underwriting...